Current Trends in Therapeutic Outcomes Among Patients With Metastatic Renal Cell Carcinoma of the Spine: A Systematic Review and Meta-Analysis Authors: Tobechukwu C. Ndika, Joshua Woo, Brandon T. Lee, Eli Johnson, Ezinne Oguguo, Nicole Rivera, Emanuel J. Ray, Adedotun Bello, Jessica D’wambe Tiako, Liban Mohamed, Sheng-Fu Larry Lo, Daniel M. Sciubba, Rafael De la Garza Ramos, John E. O’Toole, Pakawat Chongsathidkiet, Tara Dalton, Kerri-Anne Crowell, Megan Von Isenburg, Trey Mullikin, Melissa Erickson, C. Rory Goodwin Published: 2026 ABSTRACT Study DesignSystematic Review.ObjectivesThe objective of this study was to answer two questions: (1) Did the overall survival (OS) of patients with spinal metastatic renal cell carcinoma (mRCC) improve in publications from 2017 and afterwards compared to 2016 and before? (2) Did the rate of improvement in pain or neurological deficits increase in publications from 2017 and afterwards within this population?MethodsA comprehensive search was conducted to include studies that evaluated either survival or clinical outcomes in the spinal mRCC population from 1986 to 2024.Results63 studies encompassing 1,968 patients were included. The mean age was 59.1 years and 70.85% of patients were male. Pain and neurological deficits were the most common presenting symptoms, seen in 37.5% and 36.0% of patients, respectively. Compared with earlier studies, those published during or after 2017 reported improved median OS across spine surgery (27 vs. 12.3 months), radiotherapy (41.3 vs. 10.8 months), and systemic therapy (29.01 vs. 11.45 months) groups. Meta-analysis of 1-year overall survival for patients undergoing spine surgery showed significant improvement from 2017 afterwards (p<0.05). The neurological improvement rate was significantly higher from 2017 afterwards although pain relief did not differ between publication eras.ConclusionsStudies published from 2017 onward report better survival among spinal mRCC patients than earlier studies. Since the analysis is keyed to publication era rather than the therapy each patient received, the contribution of individual modalities cannot be separated, and the improvement likely reflects advances in surgery, radiotherapy, systemic therapy, and patient selection. Introduction Renal cell carcinoma (RCC) affects over 425,000 patients worldwide, accounting for approximately 2 to 3 percent of all adult malignancies and representing the most common primary malignancy of the kidney. 1 Despite advances in detection and management, RCC remains a clinically aggressive disease. At the time of diagnosis, nearly 20-30% of patients present with metastatic disease, and an additional 20-40% of patients with localized disease eventually develop metastases. 2 Historically, metastatic RCC has been associated with poor prognosis, with median overall survival (OS) often reported as less than one year in the pre-targeted therapy era.3,4 Metastatic involvement of the osseous spine represents a clinically significant manifestation of advanced renal cell carcinoma, occurring in up to 30-40% of patients and contributing substantially to morbidity through pain, mechanical instability, and neurological compromise. 5 Starting in late 1980s, the management of metastatic renal cell carcinoma was largely limited to surgical intervention and cytokine-based systemic therapies, such as interferon-alpha (IFN-α) and interleukin-2 (IL-2, aldesleukin), both of which were associated with modest response rates and significant toxicity.6,7 During this time, the treatment of spinal metastatic disease was primarily palliative, relying on conventional external beam radiotherapy for symptom control in addition to decompressive surgery. 8 Over the past decade, the treatment landscape for metastatic RCC has undergone a paradigm shift. The widespread adoption of targeted systemic therapies, including vascular endothelial growth factor-tyrosine kinase inhibitors (VEGF-TKIs) and immune checkpoint inhibitors (ICIs), has significantly improved outcomes. 7 Advancements in local therapies, such as stereotactic body radiotherapy (SBRT) and separation surgery, have also enhanced local control, survival, and symptom relief.8,9 Contemporary guidelines now incorporate these advancements as standards of care. 10 The current literature on spinal metastatic RCC is heterogeneous, with variability in treatment strategies, patient selection, and reported outcomes. In a prior systematic review, Goodwin et al 11 showed that the median survival within this population remained limited at approximately 11–12 months across studies from 1986 to 2016. While prior studies largely reflect outcomes from an era preceding the widespread adoption of modern therapies, a contemporary appraisal is needed, because the 11- to 12-month estimate derived from that era continues to be cited in prognostication and in decisions about whether to offer surgical intervention. This systematic review aims to evaluate trends in treatment and clinical outcomes among patients with spinal metastatic RCC, with a particular focus on differences in survival and symptomatic outcomes between studies published from 1986–2016 and 2017 afterwards. Methods Literature Search This study was conducted in accordance with the PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) guidelines 12 (Supplemental Digital Content 1) to assess the following research questions: (1) Did survival among patients with spinal metastatic renal cell carcinoma (mRCC) improve from 2017 afterwards compared to 2016 and before? (2) Did the rate of improvement in pain or neurological deficits increase from 2017 afterwards within this population? A medical librarian (M.V.I.) developed the search strategy using relevant keywords and subject headings. Studies were identified using the Medline (PubMed), Embase (Elsevier), Web of Science, and Cochrane databases from January 1986 to December 2024. After identification, studies were imported into Covidence, a systematic review screening software (Veritas Health, Melbourne, Australia), and duplicate articles were removed. A reproducible search strategy was documented (Supplemental Digital Content 2), and the review was registered in the International Prospective Register of Systematic Reviews (PROSPERO; registration ID: CRD420261381963). Eligibility Criteria The inclusion criteria comprised peer-reviewed clinical studies on spinal metastatic RCC that (1) were published in English; (2) described medical or surgical interventions used for treatment with specific patient numbers; and (3) provided information on pain, neurological deficits or survival. Studies not reporting patient counts, animal models, basic science studies, review articles, editorials, letters, perspective pieces, and conference presentations were excluded. Study Selection and Screening Two authors (T.C.N. and J.W.) completed an initial title and abstract screen independently, and conflicts were resolved by a third author (E.O.). Afterwards, included articles underwent full-text screening and subsequent review by 3 authors (T.C.N., E.O., and J.W.) with conflicts resolved by a fourth (N.R.). After full-text screening and review, eligible studies were included for data extraction. Quality Assessment The quality of included studies was appraised using the Oxford Centre for Evidence-Based Medicine Levels of Evidence (OCEBM) framework. 13 Each study was categorized as “high”, “medium”, or “low” quality. “High” was assigned to studies that were Class of Evidence (CoE) I or II, and the true effect could be confidently assumed to be close to the estimated effect. “Medium” was assigned to studies that were Class III or IV, and the true effect may have been different from the estimated effect. “Low” was assigned to Class V if there was very little confidence in the estimated result, no evidence, or insufficient evidence to reliably estimate an effect. The quality of each study was downgraded if evidence was indirect, results were inconsistent, no a priori subgroup analyses were present, or effect estimates were imprecise. Conversely, an overall estimation of quality could be upgraded if the magnitude of effect was large. Quality assessment was performed by 2 reviewers (T.C.N. and J.D.T.). In cases of disagreement, consensus was reached through resolution from a third author (L.M.) and a detailed review of the full text. Data Extraction Primary outcomes of interest were (1) median and 1-year OS, (2) changes in pain (pre vs post treatment) and (3) changes in sensory or motor neurological deficits within 12 months after treatment. The secondary outcome of interest was treatment related adverse effects. Data extracted from each study included the publication year and author, study design, and patient characteristics, including sex, age, metastatic presentation, and symptomatic presentation. Treatments, including surgical, radiation, and systemic therapies were collected. Outcome data, including survival and adverse events, were also collected. These elements were collected by 4 authors (T.C.N., J.W., E.O., and N.R.). To analyze temporal trends in the literature, data were divided into two publication eras: 1986-2016 and 2017-2024. This division was made based on findings published by Goodwin et al 11 which highlighted survival trends within the spinal metastatic RCC population in the former era. Data Synthesis and Statistical Analysis Descriptive data for study and patient characteristics were synthesized using means (standard deviations) for continuous variables and counts (percentages) for categorical variables. Symptomatic outcomes were compared using two-proportion z-tests rather than pooled quantitatively, as definitions of pain relief and neurological improvement were not standardized across the included studies. Median overall survival was summarized using medians (ranges) from studies that reported it. Survival was evaluated across 3 mutually inclusive treatment modalities: any spine tumor surgery, any radiotherapy, and any systemic therapy. Median survival is reported descriptively with ranges rather than pooled, because it provides no appropriate effect measure for conventional meta-analytic methods in the absence of individual patient data, and censoring differed across studies. A meta-analysis was conducted to evaluate 1-year survival among spinal mRCC patients that underwent any spine tumor surgery. Studies were eligible if the data was complete or if there was no missing data for the specific time point. This survival estimate was chosen due to having a sufficient number of studies to conduct the meta-analysis. Furthermore, it was the only survival metric that was consistently reported across studies and was suitable for meta-analysis using effect size estimates. Studies reporting 100% survival with sample sizes of 3 or fewer were excluded from the pooled analysis, as prespecified, because such estimates carry negligible sampling variance and would exert disproportionate weight in an inverse-variance model. Owing to anticipated clinical and methodological heterogeneity across studies in the meta-analysis, pooled estimates were calculated using a random-effects inverse-variance model, which accounts for both within-study sampling error and between-study variability. Statistical heterogeneity was assessed using Cochran’s Q test, the I2 statistic, and the between-study variance (τ2). Prespecified subgroup analyses stratified studies by publication era (≤2016 vs. 2017 onward) to explore potential sources of heterogeneity. Statistical significance was set at p < 0.05. All statistical analyses were conducted using the publicly available programming language, R studio (Version 4.3.2; Vienna, Austria). Results Literature Search and Data Extraction A total of 1,228 studies were identified, of which 1,115 studies were excluded during title and abstract screening. The full texts of the remaining 113 studies were assessed for eligibility, after which 50 studies were subsequently excluded. 63 remaining studies9,14-75 comprising 1,968 patients met the inclusion criteria for analysis. Details on the literature search are outlined in Figure 1.Figure 1.PRISMA diagram for identification of included studies PRISMA diagram for identification of included studies Study and Patient Characteristics Among the 63 included studies, retrospective studies comprised the largest proportion (n = 31, 49.2%), followed by case reports (n = 24, 38.1%), case series (n = 6, 9.5%), and prospective studies (n = 2, 3.2%). Forty-one studies (65.1%) were published between 1986 and 2016, whereas 22 studies (34.9%) were published between 2017 and 2024. 1,968 patients were included across all studies, with 1,018 patients reported in studies published prior to 2017 and 950 patients in studies published from 2017 afterwards. The mean patient age was 59.1 years (SD: 13.2), and most patients were male (n = 1,320). Among studies reporting metastatic presentation, 293 patients (14.9%) presented with synchronous metastases to the spine. Among studies reporting presenting symptoms, 618 patients (31.4%) presented with pain and 479 patients (24.3%) presented with neurological deficits (Table 1).Table 1.Study Characteristics and Patient Demographics for all Included Studies (n = 63)Study characteristics (n = 63) Study Design n (%) Prospective2 (3.2%) Retrospective31 (49.2%) Case Report24 (38.1%) Case Series6 (9.5%) Publication Year n (%) 1986-201641 (65.1%) 2017-202422 (34.9%)Patient Characteristics (n = 1,968) Sex No. of Reported Patients/Total (%) a Male1320/1968 (67.1%) Female543/1968 (27.6%) Mean Age (SD) 59.1 (13.2) Metastatic Presentation No. of Reported Patients/Total (%) b Synchronous293/1968 (14.9%) Metachronous296/1968 (15.0%) Presenting Symptom No. of Reported Patients/Total (%) c Pain618/1968 (31.4%) Motor or Sensory Neurological Deficit479/1968 (24.3%)a59 out of 63 studies reported data on sex for 1863 patients.b37 out of 63 studies reported data on metastatic presentation for 589 patients.c40 out of 63 studies reported data on either pain or neurological deficits at presentation. Table 1.Study Characteristics and Patient Demographics for all Included Studies (n = 63)Study characteristics (n = 63) Study Design n (%) Prospective2 (3.2%) Retrospective31 (49.2%) Case Report24 (38.1%) Case Series6 (9.5%) Publication Year n (%) 1986-201641 (65.1%) 2017-202422 (34.9%)Patient Characteristics (n = 1,968) Sex No. of Reported Patients/Total (%) a Male1320/1968 (67.1%) Female543/1968 (27.6%) Mean Age (SD) 59.1 (13.2) Metastatic Presentation No. of Reported Patients/Total (%) b Synchronous293/1968 (14.9%) Metachronous296/1968 (15.0%) Presenting Symptom No. of Reported Patients/Total (%) c Pain618/1968 (31.4%) Motor or Sensory Neurological Deficit479/1968 (24.3%)a59 out of 63 studies reported data on sex for 1863 patients.b37 out of 63 studies reported data on metastatic presentation for 589 patients.c40 out of 63 studies reported data on either pain or neurological deficits at presentation. Study Characteristics and Patient Demographics for all Included Studies (n = 63) a59 out of 63 studies reported data on sex for 1863 patients. b37 out of 63 studies reported data on metastatic presentation for 589 patients. c40 out of 63 studies reported data on either pain or neurological deficits at presentation. Treatment Characteristics Across all studies, 1,355 (68.9%) patients received spine surgery for tumor resection, 1,102 (56.0%) patients received radiotherapy during their treatment course, and 667 (33.9%) patients received either single or dual systemic therapies. Among studies that reported lesion locations, 1,537 lesions were identified, most commonly involving the thoracic spine (n = 781, 50.8%), followed by the lumbar (n = 477, 31.0%) and cervical spine (n = 160, 10.4%). Among the treatment-related adverse events reported, 194 patients (14.3%) experienced post-operative complications, 90 patients (8.2%) developed radiotherapy-associated toxicities, and 202 patients (30.3%) experienced adverse effects related to systemic therapy (Table 2).Table 2.Treatment Characteristics for all Included Patients (n = 1,968)Treatment characteristics Treatment (n = 1968) N (%) Any spine surgery1355 (68.9%) Any radiotherapy1102 (56.0%) Any systemic therapy667 (33.9%) Lesion Location (n = 1537) N (%) a Cervical160 (10.4%) Cervicothoracic9 (0.6%) Thoracic781 (50.8%) Thoracolumbar35 (2.3%) Lumbar477 (31.0%) Lumbosacral26 (1.7%) Sacral49 (3.2%) Treatment-Associated Adverse Events No. of Reported Patients/Total treated Surgical complications194/1355 (14.3%) Radiotherapy adverse events90/1102 (8.2%) Systemic therapy adverse events202/667 (30.3%)a56 out of 63 studies reported treatment location for 1537 lesions. Table 2.Treatment Characteristics for all Included Patients (n = 1,968)Treatment characteristics Treatment (n = 1968) N (%) Any spine surgery1355 (68.9%) Any radiotherapy1102 (56.0%) Any systemic therapy667 (33.9%) Lesion Location (n = 1537) N (%) a Cervical160 (10.4%) Cervicothoracic9 (0.6%) Thoracic781 (50.8%) Thoracolumbar35 (2.3%) Lumbar477 (31.0%) Lumbosacral26 (1.7%) Sacral49 (3.2%) Treatment-Associated Adverse Events No. of Reported Patients/Total treated Surgical complications194/1355 (14.3%) Radiotherapy adverse events90/1102 (8.2%) Systemic therapy adverse events202/667 (30.3%)a56 out of 63 studies reported treatment location for 1537 lesions. Treatment Characteristics for all Included Patients (n = 1,968) a56 out of 63 studies reported treatment location for 1537 lesions. Survival Across all three treatment modalities, median patient survival improved from 2017 afterwards compared to 1986–2016 in studies that reported these data. Prior to 2017, the overall median survival after spine tumor surgery across 7 studies (n = 258 patients) was 12.3 months. In contrast, median survival from 2017 afterwards increased to 27 months across 8 studies (n = 372 patients). For radiotherapy, the pre-2017 median survival aggregated across 163 patients was 13 months, whereas median survival from 2017 afterwards was 41.3 months for 121 patients. Finally, for systemic therapy, median survival was 11.45 months for 174 patients between 1986 and 2016, compared to 29.01 months for 104 patients from 2017 afterwards (Table 3). 1-year overall survival (OS) rates similarly varied between studies published from 1986-2016 compared to 2017 afterwards. Before 2017, 3 studies reported 1-year OS, with an aggregate survival rate of 50% (95% CI: 35-65%). During and after 2017, 4 additional studies reported 1-year OS, with an aggregate survival rate of 83% (95% CI: 60-94%). Lastly, when combining data from all studies that reported 1-year OS rates, the survival rate was 71% (95% CI: 49-86%), with subsequent Chi-squared analysis indicating significant differences between the 1986-2016 and 2017-afterwards subgroups (p = 0.02) (Figure 2). Of note, heterogeneity across the pooled studies was substantial (I2 = 87.0%, τ2 =1.32, P <0.01). Stratification by publication era accounted for part of this variability, though residual heterogeneity remained within both subgroups.Table 3.Median survival reported across all included studiesReported median survivalAny Spine Surgery​All1986-20162017-2024N of Studies; N of patients15 studies; 630 patients7 studies; 258 patients8 studies; 372 patientsMedian and range16 (6.2 – 127)12.3 (6.2 – 16)27 (14.8 – 127)Any Radiotherapy​All≤20162017+N of Studies; N of patients12 studies; 284 patients8 studies; 163 patients4 studies; 121 patientsMedian and range13 (5.5 – 67.8)10.8 (5.5 – 16)41.3 (14.8 – 67.8)Any Systemic therapy​All≤20162017+N of Studies; N of patients9 studies; 278 patients5 studies; 174 patients4 studies; 104 patientsMedian and range20.15 (10.6 – 30.02)11.45 (10.6 – 12.3)29.01 (28 – 30.02)Figure 2.Meta-analysis for 1-year overall survival among patients who underwent any spine tumor surgery Table 3.Median survival reported across all included studiesReported median survivalAny Spine Surgery​All1986-20162017-2024N of Studies; N of patients15 studies; 630 patients7 studies; 258 patients8 studies; 372 patientsMedian and range16 (6.2 – 127)12.3 (6.2 – 16)27 (14.8 – 127)Any Radiotherapy​All≤20162017+N of Studies; N of patients12 studies; 284 patients8 studies; 163 patients4 studies; 121 patientsMedian and range13 (5.5 – 67.8)10.8 (5.5 – 16)41.3 (14.8 – 67.8)Any Systemic therapy​All≤20162017+N of Studies; N of patients9 studies; 278 patients5 studies; 174 patients4 studies; 104 patientsMedian and range20.15 (10.6 – 30.02)11.45 (10.6 – 12.3)29.01 (28 – 30.02) Median survival reported across all included studies Meta-analysis for 1-year overall survival among patients who underwent any spine tumor surgery Symptomatic Outcomes From 1986 to 2016, 267 of 366 patients (73.0%) with available pain outcome data reported improvement in pain within one year following medical and/or surgical treatment for spinal metastatic RCC. This proportion modestly increased from 2017 afterwards, with 193 of 252 patients (76.6%) reporting post-treatment pain relief, although the difference was not statistically significant (p = 0.31). Neurological improvement was also evaluated as a symptomatic outcome. From 1986 to 2016, 163 of 293 patients (55.6%) with available data demonstrated improvement in neurological deficits following treatment. In contrast, studies published from 2017 afterwards reported neurological improvement in 126 of 186 patients (67.7%), representing a statistically significant increase compared to the earlier era (p = 0.009) (Table 4.)Table 4.Symptomatic Outcomes by Treatment EraOutcome1986–2016 (improved/total presenting, %)2017–2024 (improved/total presenting, %)P ValuePain Relief267/366 (73.0%)193/252 (76.6%)0.31Neurological Improvement163/293 (55.6%)126/186 (67.7%)0.009 Table 4.Symptomatic Outcomes by Treatment EraOutcome1986–2016 (improved/total presenting, %)2017–2024 (improved/total presenting, %)P ValuePain Relief267/366 (73.0%)193/252 (76.6%)0.31Neurological Improvement163/293 (55.6%)126/186 (67.7%)0.009 Symptomatic Outcomes by Treatment Era Evidence Appraisal Of the 63 included studies, 2 (3.2%) were high quality, 36 (57.1%) were medium quality, and 25 (39.7%) were low quality. Specifically, two studies (3.2%) were categorized as level II, 19 studies (30.2%) were categorized as level III, 17 (27.0%) were categorized as level IV, and 25 (39.7%) were categorized as level V (Supplemental Digital Content 3). Discussion In this systematic review, studies published from 2017 afterwards demonstrated improved survival outcomes compared to those published from 1986 to 2016. This improvement was observed across all three treatment groups. Because the groups are mutually inclusive and the analysis is era-based, this pattern is consistent with a broad shift in care rather than with a gain attributable to any single modality. Neurological outcomes were also significantly improved in the modern era, whereas rates of pain relief remained unchanged. Notably, pain outcomes were reported inconsistently across studies, with substantial variability in the definitions of pain relief, assessment methods, timing of follow-up, and use of patient-reported outcome measures, thus limiting the ability to detect temporal differences. Also, baseline rates of pain were relatively higher in the earlier studies, potentially limiting the ability to detect further incremental improvements over time. Collectively, these findings suggest that contemporary management strategies have enhanced survival and neurological recovery, likely reflecting the combined contributions of advancements in systemic therapy, stereotactic radiotherapy, and surgical techniques. Our findings align with broader advances in mRCC treatment, as therapies targeting vascular endothelial growth factor (VEGF) pathways and immune checkpoints have substantially improved disease outcomes. 76 Moreover, improvements in systemic disease control may have translated into prolonged survival in patients with spinal mRCC thereby increasing the potential utility of local therapies such as surgery and stereotactic radiotherapy. In particular, the increase in median survival within the radiotherapy cohort may reflect the growing use of stereotactic body radiotherapy (SBRT) which allows for the high-dose, conformal treatment of radioresistant tumors like mRCC while reducing damage to surrounding tissues. Advances in Spine Tumor Surgery Our analysis demonstrated improvements in both median and 1-year overall survival from 2017 afterwards compared to 1986-2016 among patients who underwent spine tumor surgery. Similar trends were observed by Rothrock et al 77 who reported significant improvements in postoperative survival among patients with metastatic renal, breast, lung, and colon cancers over the past two decades. This ongoing improvement in survival may reflect advances in surgical techniques and perioperative care, as well as a broader shift from uniformly aggressive surgical intervention toward more multidisciplinary, goal-directed treatment strategies. Historically, radiation therapy was considered the mainstay for spine tumors, with surgery reserved for complex cases. 78 Early surgical technique relied heavily on posterior laminectomies which limited the ability to target tumors originating from more ventral elements such as the vertebral body. This led to the development of circumferential resection techniques involving partial vertebral body removal followed by stabilization, which resulted in improved outcomes. 79 Furthermore, a randomized controlled trial by Patchell et al 80 in 2005 demonstrated that decompressive surgery followed by radiotherapy was superior to radiotherapy alone for metastatic spinal cord compression, with higher rates of preserved or regained ambulation in the surgical cohort (84% vs 57%). Advances in surgical technology, patient selection, and perioperative management have likely contributed to improved outcomes. Modern spine tumor surgery incorporates neuronavigation, robotics, advanced intraoperative imaging, and other techniques that have enhanced surgical precision and individualized operative planning.81-84 Concurrently, structured decision-making frameworks have improved multidisciplinary treatment planning and patient selection by integrating neurologic, oncologic, mechanical, and systemic considerations.85,86 Collectively, these advances highlight the evolution of metastatic spine tumor management into a multidisciplinary and precision-based field in which surgery remains a cornerstone of treatment. Advances in Radiotherapy Prior to the advent of SBRT, conventional external beam radiotherapy (EBRT) served as the primary radiotherapeutic modality for the management of spinal mRCC.87,88 However, EBRT provided limited tumor control and symptomatic relief due to the relative radioresistance of RCC. 89 The introduction of SBRT in the early 2000s fundamentally transformed the treatment of RCC bone metastases.90,91 Unlike conventional EBRT, SBRT delivers ablative radiation doses with high spatial conformity, allowing steep dose gradients that maximize tumor targeting while minimizing radiation exposure to adjacent critical structures.92,93 Multiple studies have demonstrated 1- to 2-year local control rates of 80–90% following SBRT for RCC bone metastases which shows substantial improvement compared to conventional EBRT.94,95 SBRT has also demonstrated efficacy in patients who are poor surgical candidates or previously irradiated with conventional EBRT.90,96 The widespread adoption of advanced technology for treatment planning has also facilitated the integration of SBRT into modern spine oncology practice. Across multiple studies, rates of grade 3 or greater toxicity remain below 3%, and current National Comprehensive Cancer Network guidelines recommend SBRT as the preferred treatment approach for patients with RCC.10,97 SBRT’s ability to achieve durable local control and reduce neurologic deterioration from progressive epidural disease is one plausible contributor to the improvements observed here, though our data cannot isolate it. Although improved survival is likely multifactorial and attributable to concurrent advances in surgery and systemic therapy, SBRT likely contributes meaningfully through improved disease control, preservation of neurologic function, maintenance of quality of life, and the ability to safely re-irradiate previously treated lesions.94,96 The ability to re-irradiate with SBRT has been impactful given the high recurrence of mRCC at previously treated sites. 96 Advances in Systemic Therapy Historically, the management of metastatic RCC was limited to cytokine-based drugs such as interferon-α (IFN-α) and high-dose interleukin-2 (HD IL-2)7,98,99 These therapies provided modest survival benefits and were associated with substantial toxicity, although they established RCC as an immunologically responsive tumor.5,100,101 The identification of the von Hippel-Lindau (VHL) tumor suppressor gene and its role in hypoxia-inducible factor (HIF)/VEGF signaling subsequently transformed the treatment landscape for RCC. 102 VEGF-TKIs and mammalian target of rapamycin (mTOR) inhibitors emerged as effective targeted therapies by inhibiting tumor angiogenesis and downstream proliferative signaling pathways.103-105 Following the approvals of sorafenib and sunitinib in 2005 and 2006, respectively, additional VEGF-targeted and mTOR-directed therapies expanded the therapeutic armamentarium and improved median OS to approximately 22–30 months depending on risk group and treatment regimen.106-108 Given the delays between therapeutic adoption and the publication of long-term outcomes, the survival gains associated with targeted therapies likely contributed to the findings observed in our study. The introduction of ICIs in 2015 marked the third major transition in systemic therapy for metastatic RCC. 109 ICIs restore endogenous antitumor immune activity through inhibition of immune checkpoint pathways, primarily PD-1/PD-L1 and CTLA-4 signaling.102,110 Combination ICI-based regimens, including nivolumab plus ipilimumab and ICI–TKI combinations, such as pembrolizumab plus axitinib and nivolumab plus cabozantinib, have since demonstrated substantial improvements in survival compared to sunitinib monotherapy.109,111,112 Contemporary trials now report median OS ranging from approximately 46 to 56 months depending on regimen and risk stratification.113-115 Current National Comprehensive Cancer Network (NCCN) guidelines therefore recommend ICI-based combinations as preferred first-line therapy for advanced clear-cell RCC. 10 Despite being unable to stratify this review based on treatment received, we believe the emergence of modern immunotherapy has likely contributed to improved survival in this population. The Role of Multidisciplinary Care The management of spinal metastases has progressively transitioned from a specialty driven approach to a coordinated, multidisciplinary model that incorporates expertise from various medical and surgical specialties.116,117 This model has been shown to facilitate timely treatment selection, aid care coordination, and improve patient outcomes.118,119 Also, the development of structured decision-making frameworks, such as the Neurologic, Oncologic, Mechanical, and Systemic (NOMS) paradigm, has strengthened multidisciplinary care by providing a comprehensive method for integrating neurologic status, tumor biology, mechanical stability, and systemic disease burden into individualized treatment planning. 85 Beyond directing oncologic therapy, multidisciplinary care places greater emphasis on neurologic function, symptom control, and overall performance status, all of which are recognized determinants of prognosis in patients with metastatic spine disease.80,120 Furthermore, the integration of rehabilitation and palliative care into modern oncology practice has been associated with meaningful improvements in symptom management and overall quality of life for patients with advanced cancer.121,122 Although the studies included in this review did not directly evaluate multidisciplinary care pathways, the growing incorporation of this model may represent an additional contributor to the data observed in this study. Clinical Presentation and Patient Selection The clinical presentation of spinal metastatic RCC is heterogeneous, and it influences both the treatment selected and the outcome achieved. Patients may present with an incidentally identified lesion in the absence of symptoms, with mechanical axial pain arising from vertebral body compromise, or with high-grade epidural spinal cord compression and a progressing neurological deficit. Pain and neurological deficit were the two most common presenting features in the studies reviewed here, but presentation was characterized inconsistently and was rarely reported in a form that permitted stratification of outcomes. Presenting neurological status is among the strongest determinants of post-treatment function, because patients who remain ambulatory at presentation are considerably more likely to preserve ambulation than those presenting with an established deficit. 80 The degree of mechanical instability and the extent of epidural disease, formalized in the Spinal Instability Neoplastic Score and the epidural spinal cord compression grading scale, largely determine whether a patient is offered separation surgery, instrumented stabilization, radiotherapy, or systemic therapy alone, and these frameworks are themselves products of the modern era rather than fixed features of practice across the period reviewed.85,86 Performance status and systemic disease burden govern both eligibility for aggressive local therapy and anticipated survival. Some portion of the improvement observed in the modern era may therefore reflect an evolution in how patients present and are selected for treatment, including earlier detection through more frequent surveillance imaging and a greater willingness to intervene before neurological deterioration, rather than improvements in treatment efficacy alone. None of these characteristics could be extracted from the included studies with sufficient consistency to adjust for, and they should be regarded as potential confounders of the temporal trends described here. Limitations and Future Directions This systematic review has some notable limitations. The overall evidence base was limited by both study design and methodological quality. Only 2 of the 63 included studies (3.2%) were prospective and most of the studies were of medium quality. As a result, the predominance of retrospective studies and case reports may limit causal inference and increase the potential for bias. There was also substantial heterogeneity across studies with respect to patient populations, treatment strategies, and outcome reporting. This was particularly evident for symptomatic outcomes, as definitions of pain relief and neurological improvement were not standardized. The quantitative synthesis rests on a narrower base than the review as a whole. Seven studies reported 1-year overall survival following spine tumor surgery in a form suitable for pooling, 3 from 1986–2016 and 4 from 2017 onward, and the resulting confidence intervals are correspondingly wide. The pooled estimates should be interpreted as hypothesis-generating rather than definitive. Additionally, publication year was used as a surrogate for the treatment era, which may not accurately reflect the timing of therapeutic advancements at the individual patient level. The use of aggregated data further limited the ability to adjust for important patient-level factors, including disease burden, functional status, and treatment sequencing. Furthermore, given the design of this study, the absence of individual patient-level data limited the ability to determine the independent effects of each treatment modality or evaluate potential synergistic interactions between therapies. As a result, formal adjustment for these combined treatment effects was not possible. Survival was evaluated across three mutually inclusive treatment groups, as most patients received more than one modality during their treatment course. The modality-specific survival estimates therefore describe the outcomes of patients who received a given therapy rather than the independent effect of that therapy and should not be read as a comparison between treatment strategies. Finally, the potential for publication bias must be considered, as studies reporting more favorable outcomes may be disproportionately represented. Future studies should focus on prospective, multicenter designs with standardized definitions of both survival and symptomatic outcomes to improve comparability across cohorts. The small number of poolable studies reflects prevailing reporting practice, in which survival is presented as a median without the accompanying summary statistics or individual patient data required for conventional meta-analytic methods. Standardized reporting of 1- and 2-year overall survival with measures of precision would permit more robust quantitative synthesis in this population. In addition, further investigation is needed to define optimal treatment sequencing and identify populations most likely to benefit from specific therapeutic strategies. Notably, the survival benchmarks in routine clinical use for spinal metastatic disease were largely established before the widespread adoption of stereotactic body radiotherapy, separation surgery, and immune checkpoint inhibition. A comparable era-based reappraisal is warranted across other primary histologies with a predilection for vertebral metastasis, so that the prognostic estimates used at the point of surgical decision-making reflect contemporary practice. Conclusion In this review, survival among patients with spinal metastatic renal cell carcinoma improved in the modern era. These findings are consistent with the cumulative effect of advances in systemic therapy, stereotactic radiotherapy, surgical strategy, patient selection, and multidisciplinary decision-making, though the present design cannot apportion the improvement among them. While neurological outcomes have improved in more recent cohorts, rates of pain relief remain relatively stable. Together, these results highlight a meaningful shift in the management and prognosis of spinal metastatic RCC and underscore the importance of coordinated, multimodal care to optimize both survival and functional outcomes. Supplemental Material Supplemental Material - Current Trends in Therapeutic Outcomes Among Patients With Metastatic Renal Cell Carcinoma of the Spine: A Systematic Review and Meta-Analysis Supplemental Material for Current Trends in Therapeutic Outcomes Among Patients With Metastatic Renal Cell Carcinoma of the Spine: A Systematic Review and Meta-Analysis by Tobechukwu C. Ndika, Joshua Woo, Brandon T. Lee, Eli Johnson, Ezinne Oguguo, Nicole Rivera, Emanuel J. Ray, Adedotun Bello, Jessica D’wambe Tiako, Liban Mohamed, Sheng-Fu Larry Lo, Daniel M. Sciubba, Rafael De la Garza Ramos, John E. O’Toole, Pakawat Chongsathidkiet, Tara Dalton, Kerri-Anne Crowell, Megan Von Isenburg, Trey Mullikin, Melissa Erickson and C. Rory Goodwin in Global Spine Journal. Supplemental Material - Current Trends in Therapeutic Outcomes Among Patients With Metastatic Renal Cell Carcinoma of the Spine: A Systematic Review and Meta-Analysis Supplemental Material for Current Trends in Therapeutic Outcomes Among Patients With Metastatic Renal Cell Carcinoma of the Spine: A Systematic Review and Meta-Analysis by Tobechukwu C. Ndika, Joshua Woo, Brandon T. Lee, Eli Johnson, Ezinne Oguguo, Nicole Rivera, Emanuel J. Ray, Adedotun Bello, Jessica D’wambe Tiako, Liban Mohamed, Sheng-Fu Larry Lo, Daniel M. Sciubba, Rafael De la Garza Ramos, John E. O’Toole, Pakawat Chongsathidkiet, Tara Dalton, Kerri-Anne Crowell, Megan Von Isenburg, Trey Mullikin, Melissa Erickson and C. Rory Goodwin in Global Spine Journal. Supplemental Material - Current Trends in Therapeutic Outcomes Among Patients With Metastatic Renal Cell Carcinoma of the Spine: A Systematic Review and Meta-Analysis Supplemental Material for Current Trends in Therapeutic Outcomes Among Patients With Metastatic Renal Cell Carcinoma of the Spine: A Systematic Review and Meta-Analysis by Tobechukwu C. Ndika, Joshua Woo, Brandon T. Lee, Eli Johnson, Ezinne Oguguo, Nicole Rivera, Emanuel J. Ray, Adedotun Bello, Jessica D’wambe Tiako, Liban Mohamed, Sheng-Fu Larry Lo, Daniel M. Sciubba, Rafael De la Garza Ramos, John E. O’Toole, Pakawat Chongsathidkiet, Tara Dalton, Kerri-Anne Crowell, Megan Von Isenburg, Trey Mullikin, Melissa Erickson and C. Rory Goodwin in Global Spine Journal.